Hepsor AS-i tütarettevõte rajab Tallinna kesklinna puidust kortermaja
02 sept. 2024 00h00 HE
|
HEPSOR AS
Hepsor AS-i tütarettevõte Hepsor V7 OÜ omandas kinnistu Tallinna südalinnas, aadressil Võistluse 7, kuhu on plaanis rajada unikaalne keskkonnasäästlik puidust kortermaja. Arendamisele tuleb...
Hepsor AS Subsidiary to Build a Wooden Apartment Building in Central Tallinn
02 sept. 2024 00h00 HE
|
HEPSOR AS
Hepsor V7 OÜ, a subsidiary of Hepsor AS, acquired a property in the heart of Tallinn, at Võistluse 7, where it is planned to build a unique environmentally friendly wooden apartment building. A...
Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update
30 juil. 2024 07h00 HE
|
Arvinas Inc.
– Completed enrollment in the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting; continued enrollment globally in multiple clinical trials of vepdegestrant in ER+/HER2-...
Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
09 mai 2024 07h00 HE
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics today reported business highlights and financial results for the first quarter ending March 31, 2024.
Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update
07 mai 2024 07h00 HE
|
Arvinas Inc.
– Continued enrollment globally in multiple clinical studies of vepdegestrant in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting and the study...
ASSYSTEM: First-quarter 2024 consolidated revenue
25 avr. 2024 11h35 HE
|
ASSYSTEM
First-quarter 2024 consolidated revenue: €154.3m (up 7.2%) Organic growth: 5.5% vs Q1 20232023 dividend payment calendar Paris-La Défense, 25 April 2024, 5.35 p.m. (CEST) – Assystem S.A. (ISIN:...
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
11 avr. 2024 07h00 HE
|
Arvinas Inc.
– Arvinas to receive a $150 million upfront payment for the license of ARV-766 and the sale of Arvinas’ preclinical AR-V7 program, with the potential under the License Agreement for up to $1.01...
UPDATE – Tellbio’s Technology Demonstrates that Analysis of Circulating Tumor Cells Can Predict Survival Among Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Radium-223
27 mars 2024 08h34 HE
|
TellBio, Inc
-- AR-V7 expression in CTCs isolated with TellDx is an independent negative prognostic factor in patients receiving radium-223 -- -- Study shows promise of CTCs and AR-V7 as biomarkers for radium-223...
Tellbio’s Technology Demonstrates that Analysis of Circulating Tumor Cells Can Predict Survival Among Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Radium-2230
27 mars 2024 08h00 HE
|
TellBio, Inc
-- AR-V7 expression in CTCs isolated with TellDx is an independent negative prognostic factor in patients receiving radium-223 -- -- Study shows promise of CTCs and AR-V7 as biomarkers for...
NVIDIA Healthcare Launches Generative AI Microservices to Advance Drug Discovery, MedTech and Digital Health
18 mars 2024 17h16 HE
|
NVIDIA
SAN JOSE, Calif.—GTC, March 18, 2024 (GLOBE NEWSWIRE) -- NVIDIA today launched more than two dozen new microservices that allow healthcare enterprises worldwide to take advantage of the latest...